The Department of Biotechnology Engineering was established in 2002 with approval from DTE and AICTE, India, by the dynamic and proactive management of KIT\'s College of Engineering (Autonomous) Kolhapur. This move was made in recognition of the important role that biotechnology engineers were to play in the future industrial development of biotechnology related processes and products. It has a unique place in the development of Biotechnology Engineering discipline in Maharashtra. We currently offer B. Tech. (Biotechnology Engineering) programme at undergraduate and M.Tech (Biochemical Engineering and Biotechnology) programme at post graduate level. B Tech (Biotechnology Engineering) 4 years UG programme focuses more on studies of fermentative productions of various products such as insulin like biopharmaceuticals, antibiotics, fine chemicals, enzymes etc. Students completing their HSC with PCM group are to obtain at least 45% for open category and 40% for backward class category/EWS/PwD, with non -zero score in CET 2024(PCM) and JEE (MAIN) are eligible for B.Tech Biotechnology Engg. programme.

Biotechnology field in Engineering and Technological aspect encompasses many areas including Biopharmaceuticals developments, Industrial Biotechnology, Food Biotechnology, Environmental Biotechnology, Biomedical Engineering, Bioengineering, etc. Considering Biotechnology as a fundamental research, it includes different genetic technologies in Animal and Plant Biotechnology, Cell and Tissue Engineering etc. We observe tremendous developments in Biomedical diagnosis and Artificial Intelligence mimicking Biology entering into our life. Recently, the COVID-19 pandemic showed us the importance of Biotech research where every Bio-Pharma company was behind the vaccine and drug research on COVID-19. At present, the country ranks among the top 12 global destinations for Biotechnology and is the third-largest hub for biotechnology in the Asia Pacific region. As of 2023, the Indian Biotechnology industry has exceeded an estimated value of USD 92 Billion. The Indian BioPharma industry is leading in biosimilars, with the most number of biosimilars approved in the domestic market. Global Bio-Pharma Market is valued at USD 274.10 Billion in 2020 and is expected to reach USD 703.28 Billion by 2027.